Clopidogrel
Product Images NDC 67296-1840

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 67296-1840). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Redpharm Drug, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

505 (Clopidogrel 30s)

Clopidogrel Tablets, USP 75 mg label showing the product name and strength prominently. The label includes directions for pharmacists to dispense the enclosed Medication Guide and storage instructions. It states the tablet contains 97.875 mg clopidogrel bisulfate, equivalent to 75 mg clopidogrel base. The package contains 30 tablets. Manufactured by Macleods Pharmaceuticals Ltd., India, for Macleods Pharma USA, Inc.*

FDA Label Image

505 (Clopidogrel 500s)

Clopidogrel Tablets, USP 75 mg tablet bottle label from Macleods Pharma USA. The label shows the dosage strength, NDC number 33342-060-15, and storage instructions. It includes directions for pharmacists to dispense the Medication Guide and states a quantity of 500 tablets. Manufactured for Macleods Pharma USA, Inc., Princeton, NJ.*

FDA Label Image

505 (Clopidogrel 90s)

Clopidogrel Tablets, USP 75 mg carton label showing the active ingredient strength and dosage form. The label includes dosage instructions, storage conditions, pharmacist dispensing information, and manufacturer details for Macleods Pharma USA, Inc. and Macleods Pharmaceuticals Ltd. The label also displays two barcodes and package insert reference. No package size count is specified on the label.*

FDA Label Image

505 (Clopidogrel Carton 100s)

Packaging label for Clopidogrel Tablets, USP 75 mg by Macleods Pharma USA. The label shows the product name, strength (75 mg), and a count of 100 tablets (10 x 10 unit dose). Manufacturer details include Macleods Pharmaceuticals Ltd., India and Macleods Pharma USA, Inc. Additional information includes storage instructions and a barcode.*

FDA Label Image

189 (Clopidogrel Fig 3)

A forest plot chart illustrating hazard ratios with 95% confidence intervals comparing Clopidogrel and placebo across different subgroups, including Heparin/LMWH use, Aspirin dosage levels, GPIIb/IIIa antagonist use, Beta-blocker use, and ACE inhibitor use. The chart visually represents favor toward Clopidogrel or placebo along a horizontal axis marked with hazard ratio values from 0.3 to 1.4.*

FDA Label Image

Figure-1 (Clopidogrel Figure 01)

A horizontal error bar graph depicting the effect of co-administered proton pump inhibitors (PPIs) on the active metabolite area under the curve (AUC) of Clopidogrel. It shows the mean and 90% confidence intervals for Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg, relative to Clopidogrel administered alone. The X-axis presents change relative to Clopidogrel alone, ranging from 0.4 to 1.4.*

FDA Label Image

Figure-2 (Clopidogrel Figure 02)

A line graph showing the cumulative event rate (%) of cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up. It compares two groups: one receiving placebo plus aspirin and another receiving clopidogrel plus aspirin, with the clopidogrel group showing a consistently lower event rate. The graph includes a p-value of 0.00009 indicating statistical significance.*

FDA Label Image

Figure-4 (Clopidogrel Figure 04)

A survival curve chart comparing percentage of deaths before first discharge between Clopidogrel and placebo groups over 28 days. The y-axis shows percent dead, and the x-axis shows days since randomization. Clopidogrel shows a 7% proportional risk reduction in deaths compared to placebo by day 28.*

FDA Label Image

146 (Clopidogrel Figure 05)

A line graph comparing the percentage of patients with death, reinfarction, or stroke before first discharge over 28 days. It shows two curves: one for placebo and one for Clopidogrel, with Clopidogrel demonstrating a lower event percentage and a reported 9% proportional risk reduction (p = 0.002).*

FDA Label Image

Fig-7 (Clopidogrel Figure 07)

A line graph depicting cumulative event rates (%) of fatal or non-fatal vascular events over 36 months of follow-up. Two lines represent aspirin and clopidogrel treatment groups, with event rates increasing over time. A p-value of 0.045 is noted, indicating statistical comparison between the groups.*

FDA Label Image

Figure-3 (Clopidogrel Figure 3)

A forest plot showing hazard ratios with 95% confidence intervals comparing Clopidogrel versus placebo across various subgroups including age, gender, race, enzyme elevation, diabetes, previous myocardial infarction, and previous stroke. The plot visually presents the balance of favor between Clopidogrel and placebo for each subgroup and overall.*

FDA Label Image

Figure-6 (Clopidogrel Figure 6)

A forest plot chart showing odds ratios with 99% confidence intervals for various subgroups in a study comparing Clopidogrel versus placebo. Subgroups include gender, age at entry, hours since onset, systolic blood pressure, heart rate, and fibrinolytic agent administration, with an overall summary at the bottom.*

FDA Label Image

Figure-8 (Clopidogrel Figure 8)

A forest plot chart comparing hazard ratios (95% CI) for Clopidogrel versus Aspirin across various qualifying conditions: Stroke, MI (myocardial infarction), PAD (peripheral arterial disease), and overall. The horizontal axis represents hazard ratios ranging from 0.6 to 1.3, with data points plotted for each condition showing the relative favors between Clopidogrel and Aspirin.*

FDA Label Image

Structure (Clopidogrel Structure)

Chemical structure of clopidogrel shown with its molecular components, including a sulfur-containing bicyclic ring and methyl ester group. The structure also indicates association with sulfuric acid (H2SO4).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.